SurModics, Inc. (NASDAQ:SRDX)

CAPS Rating: 5 out of 5

Develops, manufactures and markets innovative surface modification and drug delivery technologies for the healthcare industry.


Player Avatar TMFCop (86.16) Submitted: 4/14/2009 9:34:22 AM : Underperform Start Price: $18.39 SRDX Score: +5.02

Drug delivery unit derives most of its profits from JNJ stent business. The pharma just reported earnings that saw the stent business generate revenues that were down 28% in the U.S., 16% worldwide. On top of that appeals court says JNJ's stent business infringed on Boston Scientific's patents. SRDX could face a rough couple of months, particularly with its own earnings due out soon.

Featured Broker Partners